afamitresgene autoleucel
| Brand name | tecelra |
|---|---|
| Active ingredient | afamitresgene autoleucel |
| Strength | 1.62 x 10^9 to 10 x 10^9 CELL/ML |
| Dosage form | Suspension |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | June 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.